Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis

被引：0
|
作者：
Donze, C. [1 ]
Guyot, M. A. [1 ]
Kwiatkowski, A. [2 ]
Hautecoeur, P. [2 ]
Massot, C. [1 ]
机构：
[1] Inst Catholique Lille, Grp Hosp, Rehabil, Lille, France
[2] Inst Catholique Lille, Grp Hosp, Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P756
引用
收藏
页码：385 / 385
页数：1
相关论文
共 50 条
  • [31] High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo
    Levy, Marion J. F.
    Garcia-Diaz, Beatriz
    Sedel, Frederic
    Baron-Van Evercooren, Anne
    Mozafari, Sabah
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [32] Effect of MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive MS: 36-Month Follow-up Data
    Vukusic, Sandra
    de Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Simon, Olivier
    Lasser, Robert
    Tourbah, Ayman
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 32 - 33
  • [33] Pharmaceutical-Grade High-Dose Biotin improves outcome in Non-active Progressive Multiple Sclerosis: Phase 3 placebo-controlled results
    Lasser, Robert
    Bendarraz, Abdelkarim
    Sedel, Frederic
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
  • [34] High Dose Pharmaceutical Grade Biotin (MD1003) Accelerates Differentiation of Murine and Grafted Human Oligodendrocyte Progenitor Cells In Vivo
    Mozafari, S.
    Levy, M. J. F.
    Garcia-Diaz, B.
    Sedel, F.
    Van Evecooren, A. Baron
    [J]. GLIA, 2023, 71 : E743 - E743
  • [35] Positive behavioral impact of high dose pharmaceutical grade Biotin, MD1003, in mitochondrial mutant mice with neuron-specific respiratory deficiency
    Campbell, G.
    Dean, J.
    McGill, K.
    Fleming, S.
    Perdomini, M.
    Bernard, D.
    Mahad, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 602 - 602
  • [36] Effect of MD1003 (high dose pharmaceutical grade biotin) on remotely monitored ambulatory activity in progressive MS: initial step count data of the phase 3 SPI2 study
    Block, V.
    Gelfand, J.
    Sedel, F.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 569 - 570
  • [37] Effect of MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of a pivotal phase III randomised double-blind placebo controlled study
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papeix, A. -C.
    Vukusic, S.
    de Seze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G. L.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, M. M. F.
    Pelletier, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 49 - 49
  • [38] Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data
    Vukusic, S.
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Lasser, R.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 401 - 402
  • [39] MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Ayman Tourbah
    Olivier Gout
    Alain Vighetto
    Véronique Deburghgraeve
    Jean Pelletier
    Caroline Papeix
    Christine Lebrun-Frenay
    Pierre Labauge
    David Brassat
    Ahmed Toosy
    David-Axel Laplaud
    Olivier Outteryck
    Thibault Moreau
    Marc Debouverie
    Pierre Clavelou
    Olivier Heinzlef
    Jérôme De Sèze
    Gilles Defer
    Frédéric Sedel
    Carl Arndt
    [J]. CNS Drugs, 2018, 32 : 661 - 672
  • [40] MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Tourbah, Ayman
    Gout, Olivier
    Vighetto, Alain
    Deburghgraeve, Veronique
    Pelletier, Jean
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Labauge, Pierre
    Brassat, David
    Toosy, Ahmed
    Laplaud, David-Axel
    Outteryck, Olivier
    Moreau, Thibault
    Debouverie, Marc
    Clavelou, Pierre
    Heinzlef, Olivier
    De Seze, Jerme
    Defer, Gilles
    Sedel, Frederic
    Arndt, Carl
    [J]. CNS DRUGS, 2018, 32 (07) : 661 - 672
12345